TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, open-label, nonrandomized trial using a largely-intermittent,
six-month tuberculosis treatment regimen among patients who will not receive isoniazid due to
the presence of initial isoniazid resistance or intolerance. Subjects are enrolled after
resistance or intolerance to isoniazid has been documented, and are treated for a total of
six months (nine months if baseline chest x-ray shows cavitation and 2-month sputum culture
is positive) with twice weekly or thrice weekly rifampin, ethambutol, and pyrazinamide.
Phase:
N/A
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
US Department of Veterans Affairs VA Office of Research and Development